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Background: Aim was to explore the association of ERCC1 and TS mRNA levels with the disease free survival (DFS)
in Chinese colorectal cancer (CRC) patients receiving oxaliplatin and 5-FU based adjuvant chemotherapy.
Methods: Total 112 Chinese stage II-III CRC patients were respectively treated by four different chemotherapy
regimens after curative operation. The TS and ERCC1 mRNA levels in primary tumor were measured by real-time
RT-PCR. Kaplan–Meier curves and log-rank tests were used for DFS analysis. The Cox proportional hazards model
was used for prognostic analysis.
Results: In univariate analysis, the hazard ratio (HR) for the mRNA expression levels of TS and ERCC1 (logTS: HR = 0.820,
95% CI = 0.600 - 1.117, P = 0.210; logERCC1: HR = 1.054, 95% CI = 0.852 - 1.304, P = 0.638) indicated no significant
association of DFS with the TS and ERCC1 mRNA levels. In multivariate analyses, tumor stage (IIIc: reference,
P = 0.083; IIb: HR = 0.240, 95% CI = 0.080 - 0.724, P = 0.011; IIc: HR < 0.0001, P = 0.977; IIIa: HR = 0.179, 95% CI = 0.012 - 2.593,
P = 0.207) was confirmed to be the independent prognostic factor for DFS. Moreover, the Kaplan-Meier DFS
curves showed that TS and ERCC1 mRNA levels were not significantly associated with the DFS (TS: P = 0.264;
ERCC1: P = 0.484).
Conclusion: The mRNA expression of ERCC1 and TS were not applicable to predict the DFS of Chinese stage
II-III CRC patients receiving 5-FU and oxaliplatin based adjuvant chemotherapy.
Keywords: Colorectal cancer, ERCC1, TS, Real-time PCR, Adjuvant chemotherapyBackground
Colorectal cancer (CRC) is the third most common can-
cer worldwide and has a high mortality rate [1]. About
608,000 deaths from CRC are estimated worldwide, ac-
counting for 8% of all cancer deaths [2,3]. Surgery is the
most common treatment for CRC, yet prognosis remains
poor [4]. As a result, considerable interest has concen-
trated on chemotherapy after surgery, such as oxaliplatin
or 5-fluorouracil (5-FU)-based adjuvant chemotherapy
[5,6]. The 5-FU is an analogue of uracil with a fluorine
atom at the C-5 position in place of hydrogen, which
disrupts RNA synthesis and the action of thymidylate* Correspondence: shengli34t@hotmail.com
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unless otherwise stated.synthase by converting to several active metabolites: fluor-
odeoxyuridine monophosphate (FdUMP), fluorodeoxyuri-
dine triphosphate (FdUTP) and fluorouridine triphosphate
(FUTP) [7]. It was reported that 5-FU-based chemotherapy
was a safe and effective treatment for elderly patients with
advanced CRC [8]. Oxaliplatin is a platinum-based drug
that has demonstrated antitumor activities in CRC both
in vitro and in vivo [9]. It was reported that oxaliplatin
based chemotherapy could significantly increase the
progression-free survival in patients with metastatic
CRC [10]. Moreover, the better efficacy and safety of
oxaliplatin combined with 5-FU as first-line chemother-
apy for elderly patients with metastatic CRC has been
proved [11]. However, there is no predictive factor for effi-
cacy of these treatments.his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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gene codes for a nucleotide excision repair protein in-
volved in the repair of radiation and chemotherapy-
induced DNA damage [12]. It has been reported that the
gene polymorphism of ERCC1 at codon 118 was a pre-
dictive factor for the tumor response to oxaliplatin/5-FU
combination chemotherapy in patients with advanced
CRC [13]. Furthermore, thymidylate synthase (TS), as
a target enzyme of 5-FU, is associated with response to
5-FU in human colorectal and gastric tumors [14,15]. It
was reported that TS genotyping could be of help in pre-
dicting toxicity to 5-FU-based chemotherapy in CRC pa-
tients [16]. However, little is known about the association
between mRNA expression levels of ERCC1 and TS and
clinical outcomes of oxaliplatin and 5-FU based adjuvant
chemotherapy in Chinese people with CRC.
In this study, we investigated the association of ERCC1
and TS mRNA levels with the disease free survival (DFS)




This study was carried out with the Institutional Ethics
Committees approval and following the Chinese Medical
Research Council guidelines. All participants gave their
written informed consent prior to entering the study.
This is a prospective study. A total of 112 Chinese CRC
patients who were treated at Jiangsu Tumor Hospital,
China, from May 2005 to January 2010 were investigated
in this study. Eligibility criterion was histological confirm-
ation of stage II-III CRC after surgery according to the
AJCC TNM classification [17].
Chemotherapy treatment
All the patients were treated with chemotherapy after
curative operation. Four types of chemotherapy regimens
were used for the treatment of CRC patients: i) the first
one was the standard FOLFOX-4 consisting of 2-hour
intravenous infusion of oxaliplatin (85 mg/m2) on day 1,
and 2-hour intravenous drip infusion of calcium folinate
(200 mg/m2) on days 1–2, followed by intravenous in-
jection of 5-FU (400 mg/m2) and continuous infusion
of 5-FU (600 mg/m2) lasting 22 h on days 1–2, every
2 weeks; ii) the second one was the modified FOL-
FOX consisting of intravenous infusion of oxaliplatin
(130 mg/m2) and 2-hour intravenous drip infusion of
folinate calcium (200 mg/m2) on day 1, followed by intra-
venous injection of 5-FU (400 mg/m2) and continuous in-
fusion of 5-FU (1000 mg/m2) over 24 h on days 1 to 3,
every 3 weeks; iii) the third one was oral XELOX consist-
ing of 2-hour intravenous infusion of oxaliplatin 130 mg/
m2 on day 1 plus oral capecitabine 850 mg/m2 twice daily
for 2 weeks in a 3-week cycle; iv) the fourth one was aconventional intravenous drip infusion including 2-hour
intravenous infusion of oxaliplatin 130 mg/m2 on day 1
and continuous infusion of 5-FU (750 mg/m2) lasting 4 h
on days 1 to 5, every 3 weeks. All the chemotherapy regi-
mens were performed by a trained nurse. The selection of
chemotherapy regimens for each patient was according to
the recommendation of an experienced expert.
After treatment, the clinical outcomes were obtained
by telephone follow-up or a return visit with the dead-
line of January 2014. DFS, which defined as the time
from the end of chemotherapy to the first event of either
recurrent disease or death, was calculated according to
follow-up data.
RNA extraction and real-time RT-PCR
RNA was extracted and purified from formalin-fixed
paraffin-embedded (FFPE) tissue samples of surgically
resected primary CRC using an RNeasy mini kit (Qiagen,
Inc.) according to the manufacturer’s instructions [18].
The cDNA of ERCC1 and TS was prepared by reverse
transcription from RNA [19]. The ABI PRISM 7700
Sequence Detection System (Perkin-Elmer Applied Bio-
systems, Foster City, CA) was used to perform TaqMan
probe-based real-time PCR reactions as previously de-
scribed [20-22]. Relative levels of mRNA transcripts were
calculated according to the comparative Ct method using
β-actin as an endogenous control [23].
Statistical analysis
The Cox proportional hazards model was used for uni-
variate and multivariate analysis of prognostic factors. The
variables included six continuous variables (age, duration
of chemotherapy courses, interval between surgery and
chemotherapy, cumulated dosage of oxaliplatin and mRNA
expression levels of ERCC1 and TS) and eight categorical
variables (sex, primary tumor location, tumor stage, tumor
differentiation, lymph node staging, nerve invasion, vascu-
lar invasion and chemotherapy regimens). The logarithms
of the TS and ERCC1 mRNA levels (logTS, logERCC1)
were calculated for fitting normal distribution as the re-
quirement of analysis. Dummy variables were consid-
ered for all the categorical variables. The chemotherapy
regimens were used as a stratification variable in all the
analyses. The backward stepwise method was used in the
multivariate analysis base on the likelihood ratio statistics.
Kaplan–Meier curves and log-rank tests were used for
DFS analysis. Hazards ratios were used to calculate the
relative risks of recurrence or death. All tests were
two-sided, and p < 0.05 was considered as statistically
significant. Analyses were performed using SAS version
9.1 (Institute, Cary, NC) and SPSS 19.0 (IBM, Armonk,
New York). Power was calculated using the PS Power
and Sample Size Calculation, version 3.0.43 (Vanderbilt
University, Nashville, TN, USA).
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Characteristics of patients and follow-up results
Demographic details on the patients investigated in this
study are shown in Table 1. A total of 112 Chinese pa-
tients (40 females and 72 males) aged from 32 to 75 years
old (average, 52.75) were analyzed in this study. There
were 61 rectum cancer patients and 38 colon cancer pa-
tients. All patients (stage IIa, 24; stage IIb, 1; stage IIIa, 3;
stage IIIb, 53; stage IIIc, 31) underwent curative operation
and then received 4 different chemotherapy regimens, re-
spectively, including the standard FOLFOX-4 (20 cases),
modified FOLFOX (15 cases), oral XELOX (19 cases) and
conventional intravenous drip infusion (58 cases). The
median follow-up duration was 36 months (ranged from
1.2 to 78 months). Relapse occurred in forty-four patients
(39.3%) and eleven patients (9.8%) died of disease. The
median DFS was 36 months (minimum: 3 months; max-
imum: more than 77 months) (Table 1).
The mRNA expression levels of TS and ERCC1
The median mRNA expression level of TS, relative to
the housekeeping gene β-actin, was 2.86 × 10−1 (mini-
mum expression, 2.7 × 10−2; maximum expression, 6.31).
The median mRNA expression level of ERCC1, relative
to the housekeeping gene β-actin, was 1.7 × 10−3 (mini-
mum, 8.57 × 10−5; maximum, 6.7 × 10−2). In addition,
when analyzed by sex and age, no significant association
between the TS or ERCC1 mRNA levels and these pa-
rameters was found (P > 0.05).
Association of DFS with TS and ERCC1 mRNA levels
For the univariate analysis, the hazard ratio (HR) for the
mRNA expression levels of TS and ERCC1 (logTS: HR =
0.820, 95% CI = 0.600 - 1.117, P = 0.210; logERCC1: HR =
1.054, 95% CI = 0.852 - 1.304, P = 0.638) indicated that
there was no significant association of DFS with the
mRNA expression levels of TS and ERCC1 in Chinese
CRC patients treated with oxaliplatin and 5-FU based ad-
juvant chemotherapy (Table 2).
Factors considered in the multivariate analyses included
age, sex (male, female; reference category: female), tumor
stage (stage IIa, stage IIb, stage IIIa, stage IIIb, stage IIIc;
reference category: stage IIIc), tumor differentiation (high,
high or medium, medium, medium or low, low; reference
category: low), primary tumor location (rectum, colon; ref-
erence category: rectum), lymph node staging (N0, N1,
N2; reference category: N2), vascular invasion (positive,
negative; reference category: positive), nerve invasion
(positive, negative; reference category: positive), interval
between surgery and chemotherapy, duration of chemo-
therapy course, cumulated dosage of oxaliplatin as well as
the mRNA expression levels of TS and ERCC1. It is clearly
showed that only the tumor stage (tumor stage IIIc, refer-
ence, P = 0.083; tumor stage IIb, HR = 0.240, 95% CI =0.080 - 0.724, P = 0.011; tumor stage IIc, HR < 0.0001, P =
0.977; Tumor stage IIIa, HR = 0.179, 95% CI = 0.012 -
2.593, P = 0.207) entered the model in the final step and
was confirmed to be the independent prognostic factor for
DFS. The results indicated that the DFS in the patients
with tumor stage IIb was significantly longer than that in
the patients with tumor stage IIIc. In addition, there was
no evidence to prove the association between the DFS and
the TS and ERCC1 mRNA levels (Table 3).
The patients were divided into two groups based on the
median mRNA expression levels of TS (high expression
group: > 2.86 × 10−1; low expression group: ≤ 2.86 × 10−1)
and ERCC1 (high expression group: > 1.7 × 10−3; low ex-
pression group: ≤ 1.7 × 10−3). The Kaplan–Meier DFS
curves according to the mRNA expression levels of TS
and ERCC1 all showed no significant difference between
high and low expression group (TS: P = 0.264; ERCC1:
P = 0.484), suggesting that the mRNA expression levels of
TS and ERCC1 was not significantly associated with the
DFS (Figure 1).
Discussion
The expression of ERCC1 and TS has been reported to
be related with the clinical outcomes of patients treated
with the oxaliplatin or 5-FU-based adjuvant chemotherapy
[24,25]. Nevertheless, there was no enough evidence to
prove the prognostic role of ERCC1 and TS expression in
CRC patients treated with oxaliplatin and 5-FU-based ad-
juvant chemotherapy. Therefore, we analyzed the associ-
ation of mRNA expression levels of ERCC1 and TS with
DFS in Chinese patients with stage II-III CRC in this
study. The results indicated no significant association be-
tween DFS and the mRNA expression levels of ERCC1
and TS, suggesting that the expression of ERCC1 and TS
were not applicable as the predictive factors for DFS in
Chinese stage II-III CRC patients receiving 5-FU and oxa-
liplatin based adjuvant chemotherapy.
However, the mRNA levels of ERCC1 and TS has been
reported by Shirota Y et al. to be associated with survival
of 5-FU and oxaliplatin adjuvant chemotherapy in CRC
patients [20]. It may be due to the difference in cancer
stage and ethnicity of patients. In this study, the patients
were at the stage II-III of CRC. However, the patients in
the study of Shirota Y et al. [20] were at stage IV. The
mRNA expression levels of ERCC1 and TS may vary
with different stage of cancer. In addition, the patients
were all Chinese in this study but American in the study
of Shirota Y et al. The gene expression profiles were dif-
ferent among ethnic groups [26]. Therefore, we inferred
that the response of gene ERCC1 and TS to oxaliplatin
and 5-FU based adjuvant chemotherapy might be differ-
ent between Chinese and American patients.
Some previous studies have reported that ERCC1 expres-
sion is a predictive factor for survival after chemotherapy















Stage IIa 24 21.40%
Stage IIb 1 0.90%
Stage IIIa 3 2.70%
Stage IIIb 53 47%











Standard FOLFOX-4 20 17.80%
Modified FOLFOX 15 13.40%
Oral XELOX 19 17%
Conventional intravenous drip infusion 58 51.70%
Interval of chemotherapy and surgery
Within 28 days 36 32.14%
More than 28 days 76 67.86%
Duration of chemotherapy course
1-6 weeks 21 18.75%
7-12 weeks 25 22.32%
13-18 weeks 58 51.80%
19-24 weeks 8 7.14%
Tumor differentiation
High 1 0.8%
High or medium 2 1.7%
Table 1 Demographic and clinical parameters of patients
(n = 112) (Continued)
Medium 64 57.1%
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cancer [28], gastric cancer [24]. However, there was no
evidence to prove the association between the mRNA ex-
pression of ERCC1 and DFS of stage II-III CRC patients
receiving oxaliplatin and 5-FU based adjuvant chemother-
apy in this study. It indicated that ERCC1 expression
could predict clinical outcomes of chemotherapy in can-
cers such as non-small cell lung cancer, bladder cancer,
and gastric cancer but not in stage II-III CRC.
Moreover, in this study, we found that tumor stage was
a significant prognostic factor of DFS in CRC patients re-
ceiving 5-FU and oxaliplatin based adjuvant chemother-
apy. It has been reported that the survival of advanced/
recurrent rectal cancers treated with 5-FU based chemo-
therapy was significantly associated with the tumor stage
[29]. Meanwhile, another studies reported that pathologic
stage significantly influenced the DFS of locally advanced
rectal cancer patients after preoperative chemoradiation
(5-FU or oxaliplatin) [30]. Therefore, tumor stage must be
considered in the further studies for the prognostic ana-
lysis of 5-FU and oxaliplatin based adjuvant chemotherapy
for CRC patients.
There were some notable limitations of this study.
First, power calculation (α = 0.05; TS: power 1 - β = 0.511;
ERCC1: power 1 - β = 0.656) showed that the sample size
was small for reliably accessing the association between
TS or ERCC1 expression and DFS. Thus, more studies
with larger sample size were required. Second, the follow-
up duration was short, so that further studies must be
done to verify the results of this study. Third, there wereTable 2 Univariate analyses of disease free survival
according to the cox regression model
Variable Hazard ratio 95% confidence interval P
logTS 0.820 0.602-1.118 0.210
logERCC1 1.052 0.851-1.302 0.638
logTS: the logarithms of the expression level of TS; logERCC1: the logarithms
of the expression level of ERCC1.
Table 3 Cox regression analysis for multivariate analysis
Variable Disease free survival
Hazard ratio 95% confidence interval P
Tumor stage (reference category: tumor stage IIIc) 0.083
Tumor stage IIb 0.240 0.080 - 0.724 0.011
Tumor stage IIc < 0.0001 – 0.977
Tumor stage IIIa 0.179 0.012 - 2.593 0.207
For the tumor stage IIc, the hazard ratio was so small that the 95% confidence interval could not be displayed by the software.
Figure 1 Disease free survival curves according to the expression level of TS and ERCC1. A: disease free survival curves according to the
expression level of TS. B: Disease free survival curves according to the expression level of ERCC1. 0: low expression group; 1: high expression group.
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a limitation for identifying association between TS or
ERCC1 expression and DFS in this study. In addition, the
dose of 5-FU may also affect the clinical outcomes of
chemotherapy, and we must investigate this potentially
prognostic factor in the further studies.
Conclusions
In conclusion, our data demonstrated that mRNA ex-
pression levels of ERCC1 and TS were not significantly
correlated with the DFS of Chinese stage II-III CRC pa-
tients receiving 5-FU and oxaliplatin based adjuvant
chemotherapy. It suggested that the mRNA expression
levels of ERCC1 and TS were not applicable as the pre-
dictive factors for DFS in Chinese stage II-III CRC pa-
tients receiving 5-FU and oxaliplatin based adjuvant
chemotherapy. Further investigations to clearly define
the role of ERCC1 and TS gene expression in this setting
are needed.
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